Skip to content

Stable coronary disease — management

TL;DR — Stable coronary disease management has two separable aims: reduce future cardiovascular events with systemic secondary prevention, and reduce angina with antianginal drugs or revascularization. COURAGE and ISCHEMIA found no reduction in death or myocardial infarction from a routine initial PCI/invasive strategy added to contemporary medical therapy (Boden 2007, PMID 17387127; Maron 2020, PMID 32227755). ORBITA showed that placebo effects materially influence symptom endpoints, while ORBITA-2 demonstrated a genuine placebo-controlled angina benefit from PCI when antianginal drugs were minimized (Al-Lamee 2018, PMID 29103656; Rajkumar 2023, PMID 38015442). Benefit is largest when symptoms are genuinely anginal and lesions are physiologically severe, but physiology predicts symptom response rather than proven survival benefit (Simader 2024, PMID 38759906; Foley 2025, PMID 39462291). Treatment should therefore begin by naming the patient's priority—prognosis, symptom relief, or both—and by excluding anatomy or instability that changes the evidence frame.

Define the clinical problem before choosing a treatment

“Stable CAD” is not a single state. It includes newly evaluated exertional chest symptoms, known obstructive disease, prior MI or revascularization, silent ischemia, ischemic cardiomyopathy, and angina without obstructive coronary arteries. The 2023 AHA/ACC term “chronic coronary disease” and the 2024 ESC term “chronic coronary syndromes” both emphasize changing risk over time (Virani 2023, PMID 37471501; Vrints 2024, PMID 39210710).

Question Why it changes management
Are symptoms stable? Rest pain, accelerating symptoms, instability, or myocardial injury move the patient into an ACS pathway
Is the symptom likely angina? PCI cannot reliably improve non-ischemic chest discomfort
Is there left-main/high-risk anatomy? Such anatomy was excluded or underrepresented in conservative-strategy trials
Is LV function severely reduced? CABG and PCI evidence diverge in ischemic cardiomyopathy
Is disease obstructive? INOCA requires functional endotyping, not stenosis-directed PCI
What is the treatment goal? Event prevention and symptom relief rely on overlapping but distinct interventions

Stable angina is usually pressure, tightness, heaviness, or discomfort provoked by exertion or emotional stress and relieved by rest or nitroglycerin, but symptom patterns are probabilistic rather than diagnostic (Joshi 2021, PMID 33944871).

The symptom–prognosis split

Intervention Symptom effect Prognostic effect in stable disease
LDL lowering Usually no immediate angina effect Reduces MI and major vascular events (CTT 2010, PMID 21067804)
Antiplatelet/selected dual-pathway therapy No direct angina relief Reduces thrombotic events with bleeding trade-off (Eikelboom 2017, PMID 28844192)
Exercise rehabilitation Improves capacity and quality of life Reduces cardiovascular mortality and hospitalization in meta-analysis (Dibben 2023, PMID 36746187)
Beta-blocker/CCB/nitrate/ranolazine Reduces angina in responsive patients No general proof of mortality benefit solely for stable angina (Joshi 2021, PMID 33944871)
PCI Relieves angina when lesion and symptom are concordant No routine reduction in death/MI over medical therapy (Maron 2020, PMID 32227755)
CABG Relieves angina; selected anatomic benefit Prognostic benefit in selected left-main/complex multivessel or ischemic-LV disease, not all stable CAD

The split prevents two recurrent errors: interpreting absence of mortality benefit as proof that PCI “does nothing,” and interpreting symptom relief as proof that PCI prevents infarction.

Multiple post-ISCHEMIA syntheses reach the same strategy interpretation (Teoh 2020, PMID 32921371; Brown 2022, PMID 34767134; Weintraub 2023, PMID 36427605). Utilization data show the trials did not change practice where measured: across 1,245,802 PCI procedures in England and Wales from 2006 to 2019, elective PCI rates for stable angina were unchanged after COURAGE (incidence rate ratio 1.06, 95% CI 0.69–1.62) and after ORBITA (0.96, 95% CI 0.74–1.23), while the proportion of elective PCI in patients without angina almost doubled from 5.1% to 9.7% (Rashid 2022, PMID 36102261).

The randomized trial arc

Trial Population/design Main quantitative finding Interpretation
COURAGE 2,287 patients; PCI + OMT vs OMT Primary death/nonfatal-MI outcome 19.0% vs 18.5%; HR 1.05 Routine PCI did not improve prognosis (Boden 2007, PMID 17387127)
ORBITA 200 patients; single-vessel disease; sham-controlled Exercise-time increment +16.6 s vs placebo; p=0.20 First blinded test showed substantial placebo/context effect (Al-Lamee 2018, PMID 29103656)
ISCHEMIA 5,179 patients; moderate/severe ischemia 5-year primary events 16.4% vs 18.2%; CI included no difference; deaths 145 vs 144 Initial invasive strategy did not reduce death/ischemic events overall (Maron 2020, PMID 32227755)
ISCHEMIA-EXTEND Median ~7-year follow-up All-cause mortality 12.7% vs 13.4%; lower CV but higher non-CV mortality with invasive strategy No net survival advantage; cause-specific split remains unexplained (Hochman 2023, PMID 36335918)
ORBITA-2 301 randomized; little/no antianginal therapy; sham-controlled Angina symptom score 2.9 vs 5.6; OR 2.21 favoring PCI PCI has a true symptom effect as monotherapy (Rajkumar 2023, PMID 38015442)

COURAGE used intensive medical therapy and showed no event advantage from upfront PCI (Boden 2007, PMID 17387127). ISCHEMIA extended that result to patients selected for at least moderate ischemia, after excluding unacceptable left-main disease by coronary CT in most participants (Maron 2020, PMID 32227755).

ISCHEMIA did not prove that anatomy is irrelevant, that no patient should undergo angiography, or that revascularization never improves quality of life. It tested an initial strategy in a selected, stable population; crossovers and changing hazards are part of a strategy comparison, not protocol failure (Maron 2020, PMID 32227755; Hochman 2023, PMID 36335918).

Placebo-controlled interventional cardiology

Unblinded procedures produce expectation, attention, medication, and recovery effects. ORBITA made these effects measurable and showed that symptom and exercise outcomes can improve in both PCI and sham groups (Al-Lamee 2018, PMID 29103656).

ORBITA-2 changed the inference by reducing background antianginal therapy and using a daily symptom endpoint: PCI produced greater angina relief than placebo (Rajkumar 2023, PMID 38015442). Subsequent analyses sharpened selection:

  • Symptoms more typical of angina predicted larger placebo-controlled PCI benefit (Simader 2024, PMID 38759906).
  • Lower FFR/iFR values predicted greater placebo-subtracted symptom improvement (Foley 2025, PMID 39462291).
  • Ischemia on dobutamine stress echocardiography also predicted response in ORBITA-2 analysis (Ahmed-Jushuf 2025, PMID 40335250).

These findings support concordance among symptom, physiology, and lesion. They do not create a mortality indication for PCI.

Antianginal pharmacotherapy

Class Main role Common constraints
Short-acting nitrate Rapid relief and pre-exertion prophylaxis Hypotension; tolerance; dangerous interaction with PDE-5 inhibitors
Beta-blocker Reduces heart rate and demand; useful with prior MI/LV dysfunction or tachycardia Bradycardia, fatigue, bronchospasm in susceptible patients
Dihydropyridine CCB Vasodilation; combines with beta-blocker Edema, headache, hypotension
Non-dihydropyridine CCB Rate control and vasodilation Bradycardia/AV block; avoid in significant systolic dysfunction
Long-acting nitrate Prophylaxis Headache, tolerance; nitrate-free interval required
Ranolazine Add-on relief without major HR/BP reduction QT prolongation and drug interactions

No universal hierarchy fits every patient. The rational sequence uses resting heart rate, blood pressure, LV function, conduction, comorbidities, adverse effects, and patient preference. Persistent symptoms despite one agent can justify combination therapy or revascularization evaluation (Joshi 2021, PMID 33944871; Virani 2023, PMID 37471501).

Event prevention is foundational

For every symptom strategy, systemic prevention continues:

  • Intensive LDL lowering reduces major vascular events by about 22% per 1 mmol/L LDL reduction (CTT 2010, PMID 21067804).
  • Antithrombotic intensity should match ischemic and bleeding risk; low-dose rivaroxaban plus aspirin reduced MACE but increased major bleeding in COMPASS (Eikelboom 2017, PMID 28844192).
  • Exercise-based cardiac rehabilitation reduced cardiovascular mortality in pooled randomized evidence (Dibben 2023, PMID 36746187).
  • A post-MI polypill improved adherence and reduced MACE compared with usual care (Castellano 2022, PMID 36018037).

PCI does not substitute for any of these interventions.

When to consider revascularization

Scenario Evidence-based purpose
Lifestyle-limiting angina despite tolerated therapy Symptom and quality-of-life improvement
Strong preference to avoid chronic antianginal escalation Shared decision after explaining procedural and durability trade-offs
Left-main or complex multivessel disease Prognostic/anatomic assessment with Heart Team
Severe ischemic LV dysfunction CABG and PCI evidence must be distinguished
Diagnostic uncertainty with high-risk findings Define anatomy and physiology
Refractory angina not amenable to PCI/CABG Consider specialized refractory-angina options and trials

For refractory angina, ORBITA-COSMIC found symptom improvement from a coronary sinus reducer versus placebo, while myocardial perfusion effects were less straightforward; the device remains a specialist, jurisdiction-dependent option (Foley 2024, PMID 38604209).

Shared decision framework

  1. State the best estimate of event benefit: routine PCI does not reduce death/MI in the trial-eligible stable population (Maron 2020, PMID 32227755).
  2. Estimate symptom benefit using frequency, limitation, medication burden, lesion physiology, and symptom–lesion concordance (Simader 2024, PMID 38759906; Foley 2025, PMID 39462291).
  3. State procedural risks, need for antiplatelet therapy, restenosis/reintervention risk, and possibility of residual symptoms.
  4. Preserve systemic secondary prevention irrespective of the procedural choice.
  5. Reassess: stable disease is a trajectory, not a one-time binary decision.

The decision should record the patient's baseline angina frequency and limitation so that benefit is judged against a measured starting point rather than post-procedure impression alone (Rajkumar 2023, PMID 38015442).

Trial arc with incompatible but complementary estimands

Trial Primary question and result Boundary
COURAGE PCI+OMT versus OMT: death/MI 19.0% versus 18.5% (HR 1.05, 95% CI 0.87–1.27) over median 4.6 years (Boden 2007, PMID 17387127). Excluded patients requiring urgent revascularization and did not use current stents/drugs.
ISCHEMIA Initial invasive versus conservative strategy: no reduction in the primary composite or death; 5-year difference −1.8 points (95% CI −4.7 to 1.0) (Maron 2020, PMID 32227755). Left-main disease was excluded by blinded CCTA; severe symptoms and low EF were underrepresented.
ISCHEMIA-EXTEND Longer follow-up found lower CV but higher non-CV mortality with no all-cause survival advantage (Hochman 2023, PMID 36335918). Cause-specific mortality divergence is hypothesis-generating and vulnerable to competing-risk interpretation.
ORBITA After medication optimization, PCI did not significantly improve exercise time beyond placebo (difference 16.6 s, 95% CI −8.9 to 42.0) (Al-Lamee 2018, PMID 29103656). Small, short, single-vessel trial; medication optimization reduced symptoms before randomization.
ORBITA-2 With little/no background antianginal therapy, PCI improved daily angina score (OR 2.21, 95% CI 1.41–3.47) (Rajkumar 2023, PMID 38015442). Demonstrates symptom efficacy, not prevention of death or MI.
ERICA In 565 patients with angina despite maximum-dose amlodipine (baseline 5.63 episodes/week), ranolazine gave 2.88 angina episodes/week versus 3.31 on placebo (p=0.028) and 2.03 versus 2.68 nitroglycerin tablets/week (p=0.014) during 6 weeks of double-blind treatment (Stone 2006, PMID 16875985). The absolute symptom effect was modest and short-term; QT, interactions, and renal/hepatic context matter.
Refractory angina device ORBITA-COSMIC found symptom improvement with a coronary sinus reducer but no improvement in its primary myocardial-perfusion endpoint (Foley 2024, PMID 38604209). Symptom and mechanistic endpoints can diverge; sham control is essential.

Medical therapy is a bundle, not a control-arm label

“OMT” changed between COURAGE and ISCHEMIA and is often incompletely achieved in practice. It includes event prevention (LDL lowering, antithrombotic selection, BP/diabetes/smoking management, rehabilitation) and symptom therapy (beta-blocker, calcium-channel blocker, nitrate, ranolazine as appropriate), plus adherence and access. Reviews spanning BARI 2D, FAME 2, COURAGE, and ISCHEMIA show that anatomy, physiology, symptoms, and competing disease determine whether revascularization adds value (Brown 2022, PMID 34767134; Joshi 2021, PMID 33944871).

Guidelines differ less than headline debates imply. Both US and ESC chronic-disease documents support medical prevention for all, revascularization for unacceptable symptoms despite therapy, and Heart-Team assessment for prognostically important anatomy; they differ in diagnostic pathways, LDL implementation, and the granularity of endotype testing (Virani 2023, PMID 37471501; Vrints 2024, PMID 39210710). Shared decisions should state the patient's target outcome—survival, MI prevention, angina relief, medication reduction, or avoiding procedures—because one strategy cannot be assumed to optimize all five.

Event prevention remains active treatment even when angiography is deferred: intensive LDL lowering has a scalable effect per 1 mmol/L reduction (CTT 2010, PMID 21067804), selected high-risk patients may benefit from rivaroxaban plus aspirin at a major-bleeding cost (Eikelboom 2017, PMID 28844192), and CR reduces cardiovascular mortality/hospitalization (Dibben 2023, PMID 36746187). Fixed-dose polypill evidence shows that delivery simplicity can itself improve outcomes after MI (Castellano 2022, PMID 36018037). These interventions should be measured as achieved exposure, not merely prescribed at baseline.

The prevention ladder is supported by incremental outcome trials: ezetimibe after ACS, PCSK9 inhibition in established ASCVD, and pathway-specific inflammation in CANTOS each reduced events on top of background care (Cannon 2015, PMID 26039521; Sabatine 2017, PMID 28304224; Ridker 2017, PMID 28845751). SELECT adds event evidence for obesity without diabetes (Lincoff 2023, PMID 37952131). These therapies address different residual-risk axes and should not be ranked by relative effect alone without baseline risk, follow-up, harms, and cost.

Long follow-up and symptom strata prevent false unanimity

MASS II randomized 611 patients with stable multivessel disease and preserved ventricular function. At 10 years, survival was 74.9% with CABG, 75.1% with PCI, and 69.0% with medical treatment (P=0.089), while MI was 10.3%, 13.3%, and 20.7% and additional revascularization 7.4%, 41.9%, and 39.4%, respectively (Hueb 2010, PMID 20733102). Its single-center, older-technology setting limits transport, but the component pattern shows why a neutral survival comparison can coexist with large differences in MI, repeat procedures, and angina.

In ISCHEMIA's comprehensive quality-of-life substudy, the invasive strategy improved the SAQ summary score by only 1.4 points on average (95% CI 0.2–2.5), but by 3.7 points (95% CI 1.6–5.8) among participants with more frequent baseline angina and not consistently among those with rare/absent angina (Mark 2022, PMID 35259918). Baseline symptom frequency is therefore an effect modifier central to shared decisions, not a cosmetic subgroup.

Drug evidence carries different limitations. Across four ranolazine trials (1,737 participants), angina frequency and nitroglycerin use improved similarly in women and men, but exercise-test gains were smaller in women; the discordance may reflect exercise endpoints or baseline differences rather than a true sex-specific symptom effect (Wenger 2007, PMID 17196454). In the observational REACH registry, beta-blocker use was not associated with lower cardiovascular death/MI/stroke among matched patients with prior MI (HR 0.90, 95% CI 0.79–1.03) or CAD without MI (HR 0.92, 95% CI 0.79–1.08), although recent MI showed a favorable secondary-outcome association (Bangalore 2012, PMID 23032550). This cannot replace randomization, but it narrows claims of class-wide chronic prognostic benefit.

Open questions

  • Can a prospectively validated score combining symptom phenotype, FFR/iFR, stress imaging, and psychosocial factors predict placebo-controlled PCI response accurately enough for routine use? (Simader 2024, PMID 38759906; Foley 2025, PMID 39462291)
  • What explains the lower cardiovascular but higher non-cardiovascular mortality in ISCHEMIA-EXTEND? (Hochman 2023, PMID 36335918)
  • Which stable-CAD subgroups excluded from ISCHEMIA derive a survival advantage from early revascularization?
  • How durable is sham-controlled symptom benefit beyond the ORBITA-2 follow-up horizon? (Rajkumar 2023, PMID 38015442)
  • Can refractory-angina devices improve objective perfusion and function as well as symptoms? (Foley 2024, PMID 38604209)

References

  1. Boden WE, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-16. PMID 17387127
  2. Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382:1395-1407. PMID 32227755
  3. Al-Lamee R, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31-40. PMID 29103656
  4. Rajkumar CA, et al. A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina. N Engl J Med. 2023;389:2319-2330. PMID 38015442
  5. Simader FA, et al. Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease. J Am Coll Cardiol. 2024;84:13-24. PMID 38759906
  6. Foley MJ, et al. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease. Circulation. 2025;151:202-214. PMID 39462291
  7. Virani SS, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9-e119. PMID 37471501
  8. Vrints C, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415-3537. PMID 39210710
  9. Joshi PH, et al. Diagnosis and Management of Stable Angina: A Review. JAMA. 2021;325:1765-1778. PMID 33944871
  10. Cholesterol Treatment Trialists’ (CTT) Collaboration, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. PMID 21067804
  11. Eikelboom JW, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319-1330. PMID 28844192
  12. Dibben GO, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J. 2023;44:452-469. PMID 36746187
  13. Teoh Z, et al. COURAGE, ORBITA, and ISCHEMIA: Percutaneous Coronary Intervention for Stable Coronary Artery Disease. Interv Cardiol Clin. 2020;9:469-482. PMID 32921371
  14. Brown DL, et al. Optimal Medical Therapy as First-Line Therapy for Chronic Coronary Syndromes: Lessons from COURAGE, BARI 2D, FAME 2, and ISCHEMIA. Cardiovasc Drugs Ther. 2022;36:1039-1045. PMID 34767134
  15. Rashid M, et al. Rates of Elective Percutaneous Coronary Intervention in England and Wales: Impact of COURAGE and ORBITA Trials. J Am Heart Assoc. 2022;11:e025426. PMID 36102261
  16. Weintraub WS, et al. Percutaneous coronary intervention from COURAGE to ISCHEMIA and beyond. Int J Cardiol. 2023;373:39-43. PMID 36427605
  17. Hochman JS, et al. Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation. 2023;147:8-19. PMID 36335918
  18. Ahmed-Jushuf F, et al. Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI: Results From the ORBITA-2 Trial. J Am Coll Cardiol. 2025;85:1740-1753. PMID 40335250
  19. Castellano JM, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387:967-977. PMID 36018037
  20. Foley MJ, et al. Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial. Lancet. 2024;403:1543-1553. PMID 38604209
  21. Stone PH, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48:566-75. PMID 16875985
  22. Cannon CP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372:2387-97. PMID 26039521
  23. Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713-1722. PMID 28304224
  24. Ridker PM, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377:1119-1131. PMID 28845751
  25. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232. PMID 37952131
  26. Hueb W, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2010;122:949-957. PMID 20733102
  27. Mark DB, et al. Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. Circulation. 2022;145:1294-1307. PMID 35259918
  28. Wenger NK, et al. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. Am J Cardiol. 2007;99:11-18. PMID 17196454
  29. Bangalore S, et al. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340-1349. PMID 23032550